BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 8361757)

  • 1. H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts.
    Cuadrado A; Bruder JT; Heidaran MA; App H; Rapp UR; Aaronson SA
    Oncogene; 1993 Sep; 8(9):2443-8. PubMed ID: 8361757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. smg/rap1/Krev-1 p21s inhibit the signal pathway to the c-fos promoter/enhancer from c-Ki-ras p21 but not from c-raf-1 kinase in NIH3T3 cells.
    Sakoda T; Kaibuchi K; Kishi K; Kishida S; Doi K; Hoshino M; Hattori S; Takai Y
    Oncogene; 1992 Sep; 7(9):1705-11. PubMed ID: 1323817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines.
    Ratnam S; Kent C
    Arch Biochem Biophys; 1995 Nov; 323(2):313-22. PubMed ID: 7487093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells.
    Li W; Michieli P; Alimandi M; Lorenzi MV; Wu Y; Wang LH; Heidaran MA; Pierce JH
    Oncogene; 1996 Aug; 13(4):731-7. PubMed ID: 8761294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras controls coupling of growth factor receptors and protein kinase C in the membrane to Raf-1 and B-Raf protein serine kinases in the cytosol.
    Troppmair J; Bruder JT; App H; Cai H; Liptak L; Szeberényi J; Cooper GM; Rapp UR
    Oncogene; 1992 Sep; 7(9):1867-73. PubMed ID: 1386920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J; Jiang B; Coffey RJ; Barnard J
    Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of the p72-74 RAF-1 kinase in 3T3 fibroblasts expressing ras or src oncogenes.
    Reed JC; Yum S; Cuddy MP; Turner BC; Rapp UR
    Cell Growth Differ; 1991 May; 2(5):235-43. PubMed ID: 1888699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells.
    Ulkü AS; Schäfer R; Der CJ
    Mol Cancer Res; 2003 Dec; 1(14):1077-88. PubMed ID: 14707291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase C-epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity.
    Ueffing M; Lovrić J; Philipp A; Mischak H; Kolch W
    Oncogene; 1997 Dec; 15(24):2921-7. PubMed ID: 9416835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.
    Cox AD; Brtva TR; Lowe DG; Der CJ
    Oncogene; 1994 Nov; 9(11):3281-8. PubMed ID: 7936652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
    Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
    Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells.
    Michieli P; Li W; Lorenzi MV; Miki T; Zakut R; Givol D; Pierce JH
    Oncogene; 1996 Feb; 12(4):775-84. PubMed ID: 8632899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.
    Saez R; Chan AM; Miki T; Aaronson SA
    Oncogene; 1994 Oct; 9(10):2977-82. PubMed ID: 8084601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
    Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
    Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TC21 and Ras share indistinguishable transforming and differentiating activities.
    Graham SM; Oldham SM; Martin CB; Drugan JK; Zohn IE; Campbell S; Der CJ
    Oncogene; 1999 Mar; 18(12):2107-16. PubMed ID: 10321735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase.
    Cacace AM; Ueffing M; Philipp A; Han EK; Kolch W; Weinstein IB
    Oncogene; 1996 Dec; 13(12):2517-26. PubMed ID: 9000126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism.
    Arai H; Escobedo JA
    Mol Pharmacol; 1996 Sep; 50(3):522-8. PubMed ID: 8794890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergism between two growth regulatory pathways: cooperative transformation of NIH3T3 cells by G alpha 12 and c-raf-1.
    Zhang Y; Saez R; Leal MA; Chan AM
    Oncogene; 1996 Jun; 12(11):2377-83. PubMed ID: 8649778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.